Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13999399 | 0.86 | LMNA (0.41) | LMNAALDH1A1MCL1POLBMEN1 | |
| SCHEMBL17130499 | 0.83 | FAAH (0.46) | LMNAMEN1FAAHMAPK1KMT2A | |
| SCHEMBL21661487 | 0.81 | HDAC1 (0.48) | ALDH1A1 | |
| SCHEMBL12138292 | 0.81 | MEN1 (0.52) | ALDH1A1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL3542942 | 0.80 | LMNA (0.40) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL961931 | 0.79 | CTSD (0.50) | LMNAALDH1A1POLBMEN1FAAH | |
| SCHEMBL16638655 | 0.77 | LMNA (0.43) | LMNAMCL1POLB | |
| SCHEMBL25793564 | 0.77 | ALDH1A1 (0.42) | ALDH1A1POLBMEN1FAAHKMT2A | |
| SCHEMBL21661488 | 0.76 | CA12 (0.33) | ALDH1A1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL13282148 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024100139-A1 | USE OF IFN-I ACTIVITY AS A BIOMARKER FOR TLR INHIBITOR TREATMENT | MERCK PATENT GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023103906-A1 | KRAS G12D INHIBITOR AND USE IN MEDICINE | 贝达药业股份有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| US-20200316051-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| EP-3119757-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | PFIZER (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20180042926-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-9789110-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170218022-A1 | TARGETED CONFORMATIONALLY-CONSTRAINED KINKED ENDOSOMAL DISRUPTING PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160303125-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | US | disclosed |
| WO-2015140658-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | PFIZER INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-20150259323-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150166486-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-18 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| US-20130059800-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | SEATTLE GENETICS INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX7, P2RX3, P2RX1 | LMNA 1972/4885ALDH1A1 3524/4885MCL1 3829/4885 |
| US-20170218022-A1 | TARGETED CONFORMATIONALLY-CONSTRAINED KINKED ENDOSOMAL DISRUPTING PEPTIDES | NPC1, NPC1L1, NSF | LMNA 574/4885ALDH1A1 4819/4885MCL1 1678/4885 |
| US-20150259323-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, LCLAT1, DGAT1 | LMNA 1913/4885ALDH1A1 1034/4885MCL1 2214/4885 |
| US-20130059800-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | CCNB2, CCNB3, CCNB1 | LMNA 1581/4885ALDH1A1 3010/4885MCL1 19/4885 |
| US-20200316051-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | LMNA 2202/4885ALDH1A1 2071/4885MCL1 2722/4885 |
| US-20150166486-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS | SYK, ZAP70, TYRO3 | LMNA 4876/4885ALDH1A1 4142/4885MCL1 2714/4885 |
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | LMNA 1996/4885ALDH1A1 422/4885MCL1 633/4885 |
| US-20160303125-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, LCLAT1, DGAT1 | LMNA 1913/4885ALDH1A1 1034/4885MCL1 2214/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | LMNA 1733/4885ALDH1A1 2764/4885MCL1 600/4885 |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | LMNA 4811/4885ALDH1A1 4035/4885MCL1 788/4885 |
| US-20180042926-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, LCLAT1, DGAT1 | LMNA 1913/4885ALDH1A1 1034/4885MCL1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.